Richard Purcell - RespireRx Pharmaceuticals Senior Vice President - Research and Development
| RSPIDelisted Stock | USD 0.01 0.00 0.00% |
President
Mr. Richard Purcell is the Senior Vice President of Research and Development of the Company. In addition to his role at the Company, Richard Purcell is the Acting President Chief Operating Officer and a director of Cynvec, LLC, a private company. He is also the President and CEO of intelliSant, Inc., a private company. He is a biopharmaceutical development specialist, with extensive experience in providing consulting services to financial, VC, and startup companies to concentrate on new business strategy and clinical development of novel compounds. Previously, Mr. Purcell was president of ClinPro, Inc., a midsized clinical research organization, where he led this fullservice, technology driven CRO specializing in Phase I, II, and III clinical trial management. His work included the design and implementation of a number of early stage clinical development programs. Prior to joining ClinPro, Mr. Purcell worked for SCP Communications, a medical communications company, where he served as Corporationrationrate Vice President and General Manager of the Clinical Programs Division. Mr. Purcell previously headed the Life Sciences Consulting Group for Kline and Company. Mr. Purcell started his career as a molecular biologist, where he developed and patented a second generation TPA with increased halflife. He has also conducted primary research and published manuscripts on the topics of AIDS and immunomodulators. Mr. Purcell graduated with a degree in Biochemical Sciences from Princeton University, and attended Rutgers Graduate School of Management focusing in marketing and finance.
| Age | 62 |
| Phone | 201 444 4947 |
| Web | https://www.respirerx.com |
RespireRx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (8.3401) % which means that it has lost $8.3401 on every $100 spent on assets. This is way below average. RespireRx Pharmaceuticals' management efficiency ratios could be used to measure how well RespireRx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.RespireRx Pharmaceuticals currently holds 2.42 M in liabilities. RespireRx Pharmaceuticals has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist RespireRx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, RespireRx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RespireRx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RespireRx to invest in growth at high rates of return. When we think about RespireRx Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | PRESIDENT Age | ||
| Mingqin Li | Sino Biopharmaceutical Ltd | 64 | |
| Hsin Tse | Sino Biopharmaceutical Ltd | 53 | |
| Wei Ye | Sino Biopharmaceutical Ltd | 60 | |
| Steven Perrin | Eledon Pharmaceuticals | 59 | |
| Wun Tse | Sino Biopharmaceutical Ltd | 56 | |
| Fai Chia | Sino Biopharmaceutical Ltd | 65 | |
Management Performance
| Return On Asset | -8.34 |
RespireRx Pharmaceuticals Leadership Team
Elected by the shareholders, the RespireRx Pharmaceuticals' board of directors comprises two types of representatives: RespireRx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RespireRx. The board's role is to monitor RespireRx Pharmaceuticals' management team and ensure that shareholders' interests are well served. RespireRx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RespireRx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff Margolis, VP, Treasurer, Secretary and Director | ||
| Richard Purcell, Senior Vice President - Research and Development | ||
| Arvid Carlsson, Consultant | ||
| David Dickason, VP Devel | ||
| Arnold Lippa, Executive Chairman and Chief Scientific Officer | ||
| Marc Radin, Controller |
RespireRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is RespireRx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in RespireRx Pink Sheet
If you are still planning to invest in RespireRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RespireRx Pharmaceuticals' history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |